Savara (NASDAQ:SVRA) Now Covered by HC Wainwright

Research analysts at HC Wainwright assumed coverage on shares of Savara (NASDAQ:SVRA) in a note issued to investors on Thursday, Benzinga reports. The firm set a “buy” rating and a $10.00 price target on the stock. HC Wainwright‘s price objective indicates a potential upside of 100.40% from the stock’s current price.

Several other brokerages have also recently weighed in on SVRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research note on Thursday, October 15th. Royal Bank Of Canada set a $10.00 price target on shares of Savara in a research report on Wednesday, October 7th. Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. JPMorgan Chase & Co. began coverage on shares of Savara in a research report on Wednesday, October 7th. They set an “overweight” rating and a $12.00 price objective for the company. Finally, Citigroup restated a “market outperform” rating on shares of Savara in a research report on Wednesday, October 7th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.25.

Savara Trading Up 1.4%

Shares of NASDAQ:SVRA opened at $4.99 on Thursday. The stock’s 50 day moving average price is $4.96 and its 200 day moving average price is $5.35. The company has a debt-to-equity ratio of 0.28, a current ratio of 8.55 and a quick ratio of 10.13. Savara has a 12 month low of $4.03 and a 12 month high of $7.01.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. As a group, equities research analysts anticipate that Savara will post -0.66 EPS for the current fiscal year.

Hedge Funds Weigh In On Savara

A number of institutional investors have recently bought and sold shares of SVRA. Sterling Capital Management LLC lifted its stake in Savara by 842.8% during the third quarter. Sterling Capital Management LLC now owns 5,063 shares of the company’s stock valued at $26,000 after buying an additional 4,526 shares in the last quarter. Principal Financial Group Inc. purchased a new position in shares of Savara in the first quarter worth approximately $57,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Savara during the third quarter valued at approximately $54,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Savara during the second quarter valued at approximately $69,000. Finally, E Fund Management Co. Ltd. acquired a new stake in shares of Savara during the second quarter valued at approximately $77,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.